Home > Quotes > ABBV

AbbVie Inc. Stock Quote & Summary Data

ABBV 
$59.62
*  
1.02
1.74%
Get ABBV Alerts
*Delayed - data as of Sep. 17, 2014  -  Find a broker to begin trading ABBV now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    ABBV After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
1 Year Target: 66
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 9,340,817
Previous Close: $ 58.60
52 Week High /Low: $ 58.77 / $ 44.015
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 94,897,101,773
P/E Ratio: 23.02
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 18.66
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ 2.59
Annualized dividend $ 1.68
Ex Dividend Date Jul. 11, 2014
Dividend Payment Date Aug. 15, 2014
Current Yield 2.87 %
Beta 1.11

Intraday Chart

ETFs with ABBV as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
8.74% First Trust IPOX-100 Index Fund (FPX) +3.69  (8.07%)
3.67% Select Sector SPDR Fund - Health Care (XLV) +6.69  (11.57%)
3.45% iShares Dow Jones U.S. Health Care Index Fund (IYH) +14.32  (11.80%)
3.16% Vanguard Health Care ETF (VHT) +12.93  (12.31%)
1.7% SPDR S&P Dividend ETF (SDY) +2.31  (3.11%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

On January 1, 2013, AbbVie(1) became an independent company as a result of the distribution by Abbott Laboratories (Abbott) of 100 percent of the outstanding common stock of AbbVie to Abbott's shareholders. Each Abbott shareholder of record as of the close of business on December 12, 2012 (the Record Date) received one share of AbbVie common stock for each Abbott common share held as of the Record Date. AbbVie was incorporated in Delaware on April 10, 2012 to hold Abbott's former research-based pharmaceuticals business. AbbVie's common stock began trading "regular-way" under the ticker symbol "ABBV" on the New York Stock Exchange on January 2, 2013. Overview AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases.  ... More ...  

News for ABBV

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?